Antiviral target compound profile for pandemic preparedness
J
James F. Demarest
R
Ruxandra Draghia-Akli
T
Tomas Cihlar
K
Kenneth Bradley
J
John A. T. Young
R
Richa Chandra
S
Sujata Vaidyanathan
M
Margaret Chu-Moyer
C
Christopher L. Lynch
A
Andrew Campbell
K
Kumar Singh Saikatendu
J
John P. Bilello
Y
Yoshihiko Murata
A
Aeron C. Hurt
T
Timothy Tellinghuisen
L
Lee Ruggiero
R
Richard Mackman
N
Nina M. Hill
J
John C. Pottage
M
Marnix van Loock
Article Details
Journal
Nature Reviews Drug Discovery
Volume / Issue
Vol. 24, Issue 2
Published
February 01, 2025
Pages
151-152
ISSN
1474-1776
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Drug Discovery
Springer Science and Business Media LLC
ISSN: 1474-1776 Q1 Medicine
Authors (20)
J
James F. Demarest
R
Ruxandra Draghia-Akli
T
Tomas Cihlar
K
Kenneth Bradley
J
John A. T. Young
R
Richa Chandra
S
Sujata Vaidyanathan
M
Margaret Chu-Moyer
C
Christopher L. Lynch
A
Andrew Campbell
K
Kumar Singh Saikatendu
J
John P. Bilello
Y
Yoshihiko Murata
A
Aeron C. Hurt
T
Timothy Tellinghuisen
L
Lee Ruggiero
R
Richard Mackman
N
Nina M. Hill
J
John C. Pottage
M
Marnix van Loock
Related Articles from this Journal
Can multispecific biologics break the efficacy ceiling?
Asher Mullard
Jul 2026
10.1038/d41573-026-00106-5
Novel drug targets in 2025
Sorin Avram, Liliana Halip et al.
Jul 2026
10.1038/d41573-026-00102-9
The unglamourous AI wins that are quietly transforming drug discovery and development
Asher Mullard
Jul 2026
10.1038/d41573-026-00099-1
Upcoming FDA approval decisions in Q3 2026
Swetha Kota
Jul 2026
10.1038/d41573-026-00103-8
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
Asher Mullard
Jul 2026
10.1038/d41573-026-00101-w